GW Pharmaceuticals loses $8 million over last quarter

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company warned the COVID-19 pandemic could hit sales if fewer patients visit their doctors. Reports Hemp Industry Daily

Revenue in the quarter ending March 31 reached $120.6 million, up from $91 million and $109.1 million in the third and fourth quarters of 2019, respectively.

Epidiolex, a cannabidiol-based prescription medicine, was the company’s primary revenue driver, with net sales of $116.1 million in the latest quarter.

Here’s the SEC form

Here’s the full story from HID

GW Pharma trims loss to $8 million, warns virus could hit sales